Radiopharmaceuticals and Cold Kits WBAMC

THIS IS A SOURCES SOUGHT/MARKET RESEARCH ANNOUNCEMENT ONLY. This notice does not constitute a commitment by the Government. All information submitted in response to this announcement is voluntary, and the Government will not pay for information requested nor will it compensate any respondent for any cost incurred in developing information provided to the Government.

The Government anticipates a firm fixed price contract with a 12-month base period and one (1) 12- month option year. As part of its market research, the Medical Readiness Contracting Office -West (MRCO-W) is issuing this Sources Sought notice to identify and determine if there are potential sources which have the capabilities to provide RADIOPHARMACEUTICALS and COLD KITS handling the transport biohazard and radioactive materials for medical use, (see the attached product list for details). The Government may use the responses to this Sources Sought for information and planning purposes.

This notice does not constitute a Request for Quote (RFQ)/Invitation for Bid (IFB)/Request for Proposal (RFP) or a promise to issue an RFQ, IFB or RFP in the future. This notice does not commit the U.S. Government to contract for any supply or service. Further, the U.S. Government is not seeking quotes, bids or proposals at this time and will not accept unsolicited proposals in response to this source sought notice. The U.S. Government will not pay for any information or administrative costs incurred in response to this notice. Submittals will not be returned to the responder. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. However, if a competitive solicitation is released, it will be synopsized on the Government wide Point of Entry, if applicable. It is the responsibility of potential offerors to monitor the Government wide Point of Entry for additional information pertaining to this requirement. The NAICS code is 325412 Pharmaceutical Preparation Manufacturing.

Interested Vendors shall provide the following information:

1) Organization name, physical address, valid POC email address, Web site address, telephone number, SAM EUI number, business size under sources sought notice NAICS 325412.

2) Details: The vendor shall deliver Isotopes between 6:00 a.m. and 5:00 p.m., CST, Monday thru Friday for the duration of any resultant contract until otherwise specified. The vendor shall have after hour and STAT delivery as needed for expedited delivery of radiopharmaceuticals and on-call request. Isotopes must be produced locally due to shelf-life not exceeding 24 hours. If the local area is malfunctioning, FDG-18 from outside the local area shall be available for use. Reagents / Radiopharmaceuticals must be approved be approved by the FDA. Reagents / Radiopharmaceuticals must be compatible with existing Mo99/Tc99m Generator within the hospital.

Salient Characteristic for Indium-111 oxyquinoline:

• Indium in 111 oxyquinoline (oxine) must be a diagnostic radiopharmaceutical intended for radiolabeling autologous leukocytes.
• It must be supplied as a sterile, non-pyrogenic, isotonic aqueous solution with a pH range of 6.5 to 7.5.
• Each ml of the solution must contain 37 MBq, 1 mCi of indium in 111 no carrier added,>1.85 GBq/mg indium (>50 mCi/mg indium) at calibration time, 50 mg oxyquinoline, 100 mg polysorbate 80,and a 6 mg of HEPES (N-2-hydroxyethyl- piperazine-N¢-2-ethane sulfonic acid) buffer in 0.75% sodium chloride solution.
• The radionuclidic impurity limit for indium 114m must be not greater than 37kBq, 1 mCi of indium 114m per 37 MBq, 1 mCi of indium In 111 at the time of calibration.
• The radionuclidic composition at expiration time must not be less than 99.75% of indium In 111 and not more than 0.25% of indium In 114m/114.
• Chemical name must equal Indium In 111 oxyquinoline (oxine).
• The drug must be intended for single use only and contains no bacteriostatic agent.

Offeror’s capability to perform a contract of this magnitude and complexity including offeror’s capability to provide radiopharmaceuticals and cold kits for William Beaumont Army Medical Center, (WBAMC) Fort Bliss, Texas. Provide at least three (3) examples. Documentation of appropriate products must be presented in sufficient detail for the Government to determine that your company possesses the necessary means to compete for this acquisition.